NuCana plc: NuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer
10 Mar 2020
Confirmed Complete Response and Two Partial Responses Achieved in Heavily Pre-treated Population Patients had Median of Five Prior Lines of Therapy EDINBURGH, United Kingdom, March 10, 2020 (GLOBE ...
Organizations
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.